Sarepta Therapeutics, Inc. (FRA:AB3A)
Germany flag Germany · Delayed Price · Currency is EUR
17.96
-0.33 (-1.80%)
At close: Dec 1, 2025

Sarepta Therapeutics Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
1,77811,2188,16110,6436,89510,999
Upgrade
Market Cap Growth
-82.73%37.46%-23.32%54.37%-37.31%28.32%
Upgrade
Enterprise Value
2,13011,4277,85010,2056,52410,155
Upgrade
Last Close Price
17.96115.9588.08118.5680.06139.32
Upgrade
PE Ratio
-49.37----
Upgrade
PS Ratio
0.866.117.2612.1911.1724.91
Upgrade
PB Ratio
1.587.6010.5029.558.4517.66
Upgrade
P/TBV Ratio
1.627.7410.8730.148.5817.98
Upgrade
P/FCF Ratio
-----532.53
Upgrade
P/OCF Ratio
-----125.19
Upgrade
EV/Sales Ratio
1.036.226.9811.6910.5723.00
Upgrade
EV/EBITDA Ratio
26.3846.25----
Upgrade
EV/EBIT Ratio
-54.25----
Upgrade
EV/FCF Ratio
-6.56----491.69
Upgrade
Debt / Equity Ratio
0.960.881.614.201.231.41
Upgrade
Debt / EBITDA Ratio
13.433.74----
Upgrade
Debt / FCF Ratio
-----42.47
Upgrade
Asset Turnover
0.680.530.390.300.230.23
Upgrade
Inventory Turnover
2.402.103.905.214.123.90
Upgrade
Quick Ratio
1.512.743.233.635.054.99
Upgrade
Current Ratio
2.954.203.954.135.755.97
Upgrade
Return on Equity (ROE)
-21.37%19.71%-86.15%-107.16%-49.57%-70.14%
Upgrade
Return on Assets (ROA)
-1.52%3.77%-5.24%-10.68%-9.04%-14.67%
Upgrade
Return on Capital (ROIC)
-2.06%5.34%-7.90%-16.47%-14.21%-20.84%
Upgrade
Return on Capital Employed (ROCE)
-3.30%6.70%-10.30%-21.40%-16.50%-22.00%
Upgrade
Earnings Yield
-13.02%2.02%-5.94%-6.19%-5.34%-4.12%
Upgrade
FCF Yield
-18.27%-2.95%-6.40%-3.13%-6.14%0.19%
Upgrade
Buyback Yield / Dilution
2.62%-16.75%-5.53%-7.75%-4.24%-5.90%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.